BMS signs cancer therapy deal worth $1.5bn with Agenus
As part of the agreement, BMS will pay $200m upfront to Agenus, which is also eligible for up to $1.36bn in development, regulatory and commercial milestone payments and
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.